Healthcare / Pharmaceutical RetailersBSE
$43.60
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $3000.00 · quality 37.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$192M
P/E
167.7x
↑EV/EBITDA
22.4x
↑ROE
3.6%
↑Gross Margin
12.4%
↓Debt/Equity
1.47
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.7%
FCF CAGR
—
FCF margin
10.3%
FCF / Net income
17.55x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $286.6M · net income $1.7M · FCF $29.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $286.6M | $286.6M | $190.1M | $133.0M | $200.5M |
| Net Income | $1.7M | $1.7M | $-4.5M | $-11000.00 | $2.3M |
| EBITDA | $11.4M | $11.4M | $3.6M | $5.9M | $7.4M |
| EPS | 0.38 | 0.38 | -1.02 | -0.00 | 0.84 |
| Gross Margin | 12.4% | 12.4% | 11.3% | 16.3% | 12.9% |
| Operating Margin | 7.3% | 7.3% | 1.0% | 3.2% | 3.0% |
| Net Margin | 0.6% | 0.6% | -2.4% | -0.0% | 1.1% |
| Balance Sheet | |||||
| Debt/Equity | 1.47 | 1.47 | 2.33 | 1.28 | 1.15 |
| Current Ratio | 1.58 | 1.58 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $29.6M | $29.6M | $3000.00 | $-68000.00 | $-4.1M |
| Returns | |||||
| ROE | 3.6% | 3.6% | -9.9% | -0.0% | 4.5% |
| Valuation | |||||
| P/E | 167.69 | 167.69 | — | — | 68.21 |
| EV/EBITDA | 22.44 | 22.44 | 57.24 | 26.25 | 27.99 |
| P/B | 4.08 | 4.08 | 2.40 | 1.95 | 3.09 |
| Growth & Yield | |||||
| Revenue Growth | 50.7% | 50.7% | 43.0% | -33.7% | — |
| EPS Growth | 137.3% | 137.3% | -40700.0% | -100.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
116.7%
EPS terminal req.
$3.87
Spread vs growth
20.5%
5Y implied EPS CAGR
65.2%
EPS terminal req.
$4.68
Spread vs growth
72.0%
10Y implied EPS CAGR
34.8%
EPS terminal req.
$7.54
Spread vs growth
102.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+82.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.02 → 0.38
Residual
+82.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.